Page last updated: 2024-10-16

beta-alanine and Intraocular Pressure

beta-alanine has been researched along with Intraocular Pressure in 51 studies

Intraocular Pressure: The pressure of the fluids in the eye.

Research Excerpts

ExcerptRelevanceReference
"To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID)."9.30Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. ( Bacharach, J; Braswell, P; Heah, T; Khouri, AS; Kopczynski, CC; Lewis, RA; Serle, JB; Usner, DW, 2019)
"Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0."9.30Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. ( Asrani, S; Heah, T; Kopczynski, CC; Lewis, RA; Robin, AL; Serle, JB; Usner, DW, 2019)
" In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma."9.22Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022)
" The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)."9.20Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. ( Bacharach, J; Dubiner, HB; Kopczynski, CC; Levy, B; Novack, GD, 2015)
"New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed."6.94Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. ( Asrani, S; Bacharach, J; Heah, T; Holland, E; Kopczynski, CC; Lewis, RA; McKee, H; Sheng, H, 2020)
" The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q."6.87Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). ( Heah, T; Katz, LJ; Kopczynski, CC; McLaurin, E; Novack, GD; Ramirez-Davis, N; Serle, JB; Usner, DW, 2018)
"Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy."6.66New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020)
"02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0."5.34Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. ( Fechtner, RD; Heah, T; Kim, T; Kopczynski, CC; Lewis, RA; McKee, H; Myers, JS; Sheng, H; Singh, IP; Usner, DW, 2020)
"To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID)."5.30Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. ( Bacharach, J; Braswell, P; Heah, T; Khouri, AS; Kopczynski, CC; Lewis, RA; Serle, JB; Usner, DW, 2019)
"Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0."5.30Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. ( Asrani, S; Heah, T; Kopczynski, CC; Lewis, RA; Robin, AL; Serle, JB; Usner, DW, 2019)
" In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma."5.22Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022)
" The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)."5.20Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. ( Bacharach, J; Dubiner, HB; Kopczynski, CC; Levy, B; Novack, GD, 2015)
"Intraocular pressure curves were acquired over a 3-day acclimation period, 5-day dosing period (QD or BID-10 dogs/group), and 3-day recovery period."3.01Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs. ( Keys, DA; La Croix, NC; Miller, PE; Yang, VY, 2021)
"Pharmacotherapies for POAG or ocular hypertension (OHT) commonly lower IOP by increasing uveoscleral outflow or decreasing aqueous humor production."3.01Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study. ( Challa, P; Gupta, D; Heah, T; Kazemi, A; Kopczynski, C; Liu, KC; Lopez, J; McKee, H; Sit, AJ, 2021)
"04% dosed QD (P."3.01Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. ( Araie, M; Aso, K; Hollander, DA; Kanemoto, K; Kopczynski, C; Kothapalli, K; Senchyna, M; Sugiyama, K, 2021)
"New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed."2.94Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. ( Asrani, S; Bacharach, J; Heah, T; Holland, E; Kopczynski, CC; Lewis, RA; McKee, H; Sheng, H, 2020)
" The most frequently reported adverse events (AEs) were ocular, with the most frequent ocular AE being conjunctival hyperemia, with an incidence of 61%, 66%, and 14%, respectively."2.90Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). ( Heah, T; Kahook, MY; Kim, T; Kopczynski, CC; Mah, FS; Novack, GD; Raizman, MB; Ramirez-Davis, N; Serle, JB; Usner, DW, 2019)
" The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q."2.87Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). ( Heah, T; Katz, LJ; Kopczynski, CC; McLaurin, E; Novack, GD; Ramirez-Davis, N; Serle, JB; Usner, DW, 2018)
"Elevated intraocular pressure is a prime risk factor for blindness in the elderly."2.72Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. ( Batra, M; Dhanawat, M; Gupta, S; Morsy, MA; Nair, AB; Sandal, S, 2021)
"Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy."2.66New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020)
"These cataracts were overall small, 1 to 3 mm, round, oval or ring-shaped, central or paracentral with mild density."1.72Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma. ( Chang, EL; Emmel, DK; Liu, J; Sarrafpour, S; Teng, CC, 2022)
"Twenty eyes from 10 patients with Fuchs endothelial corneal dystrophy had DWEK with cataract surgery."1.62Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy. ( Davies, E; Jurkunas, U; Pineda, R, 2021)
"The intraocular pressure was 10 mm Hg in both eyes."1.56Reversible Corneal Endothelial Abnormalities With Netarsudil. ( Esfandiari, H; Tanna, AP; Teramoto, K, 2020)
"Primary open angle glaucoma (POAG) is the most common type of glaucoma, and is responsible for approximately 90% of glaucoma cases in North America."1.46Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. ( Lee, JK; Liebmann, JM, 2017)
" Ester 60 improved bioavailability of its parent ROCK inhibitor, 29 (Ki=0."1.43Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. ( deLong, MA; Heintzelman, GR; Kopczynski, CC; Laethem, CL; Lin, CW; Moore, LA; Royalty, SM; Sherman, B; Sturdivant, JM; Yingling, JD, 2016)
" Animals were dosed with AR-13324 (0."1.42Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. ( Kiel, JW; Kopczynski, CC, 2015)

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's16 (31.37)24.3611
2020's35 (68.63)2.80

Authors

AuthorsStudies
Shiuey, EJ1
Mehran, NA2
Ustaoglu, M1
Zhang, Q1
Razeghinejad, R3
Shukla, AG1
Kolomeyer, NN2
Myers, JS3
Lee, D3
Chen, YH1
Lin, WY1
Huang, YC1
Ho, WY1
Fu, CW1
Tu, CM1
Hwang, CS1
Hung, CL1
Lin, MC1
Cheng, F1
Wang, YJ1
Chen, CH1
Chou, SH1
She, MP1
Yang, CY1
Cheng, HL1
Liu, CP1
Lu, DW1
Chang, EL1
Emmel, DK1
Teng, CC1
Sarrafpour, S1
Liu, J1
Lyons, LJ1
Wu, KY1
Baratz, KH1
Sit, AJ2
Xu, H1
Thomas, MT1
Hirabayashi, MT1
An, JA1
Bronner, AW1
Jeang, LJ1
Shah, AS1
Hammer, JD1
Tuli, SS1
Goergen, NS1
Gagrani, M1
Gulati, V1
Ghate, D1
Lee, JW1
Ahn, HS1
Chang, J2
Kang, HY1
Chang, DJ1
Suh, JK1
Lee, H1
Rivera, SS1
Radunzel, N1
Boese, EA1
Bonardi, A1
Supuran, CT1
Sinha, S2
Leary, KA2
Lin, KT1
Steibel, JP2
Harman, CD2
Komáromy, AM2
Yang, VY1
Miller, PE1
Keys, DA1
La Croix, NC1
Wisely, CE1
Sheng, H3
Heah, T9
Kim, T3
Asrani, S2
Bacharach, J3
Holland, E1
McKee, H3
Lewis, RA5
Kopczynski, CC12
Tanna, AP2
Esfandiari, H1
Teramoto, K1
Chen, S1
Waxman, S1
Wang, C1
Atta, S1
Loewen, R1
Loewen, NA1
Moumneh, K1
Sheybani, A1
Fellman, RL1
Godfrey, DG1
Grover, DS1
Chen, TC1
Jurkunas, U2
Chodosh, J1
Chen, H1
McMillin, JC1
Frankfort, BJ1
Al-Mohtaseb, Z1
Singh, IP1
Fechtner, RD1
Usner, DW6
Price, MO1
Feng, MT1
Price, FW1
Gonzalez, LE1
Boylan, PM1
LoBue, SA1
Moustafa, GA1
Vu, A1
Amin, M1
Nguyen, T1
Goyal, H1
Ostler, E1
Rhee, D1
Burney, E1
Sozeri, Y1
Gupta, D1
Kazemi, A1
Challa, P2
Liu, KC1
Lopez, J1
Kopczynski, C3
Araie, M1
Sugiyama, K1
Aso, K1
Kanemoto, K1
Kothapalli, K1
Senchyna, M1
Hollander, DA1
Mehta, AA1
Kanu, LN1
Sood-Mendiratta, S1
Quinones, R1
Hawkins, A1
Lehrer, RA1
Malhotra, K1
Papas, R1
Hillman, D1
Wilensky, JT1
Aref, AA1
Vajaranant, TS1
Edward, DP1
Zaman, F1
Gieser, SC1
Schwartz, GF1
Swan, C1
Williams, JM1
Davies, E1
Pineda, R1
Li, G2
Lee, C1
Read, AT1
Wang, K1
Ha, J1
Kuhn, M1
Navarro, I2
Cui, J1
Young, K1
Gorijavolu, R1
Sulchek, T1
Farsiu, S2
Samples, J1
Ethier, CR1
Stamer, WD2
Batra, M1
Gupta, S1
Nair, AB1
Dhanawat, M1
Sandal, S1
Morsy, MA1
Kim, HM1
Tran, AQ1
Yang, C1
Dagi Glass, LR1
Anderson, AL1
Liebmann, JM1
Lee, JK1
Serle, JB4
Katz, LJ1
McLaurin, E1
Ramirez-Davis, N2
Novack, GD4
Hoy, SM1
Johnson, M1
Kahook, MY1
Mah, FS1
Raizman, MB1
Khouri, AS1
Braswell, P1
Schehlein, EM1
Robin, AL2
Dubiner, HB1
Levy, B2
Kiel, JW1
Ramirez, N1
Sturdivant, JM1
Royalty, SM1
Lin, CW1
Moore, LA1
Yingling, JD1
Laethem, CL1
Sherman, B1
Heintzelman, GR1
deLong, MA1
Mukherjee, D1
Ashpole, NE1
Sherwood, JM1
Overby, DR1
Yuan, F1
Gonzalez, P1
Shaw, PX1
Sang, A1
Wang, Y1
Ho, D1
Douglas, C1
Dia, L1
Goldberg, JL1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Double-masked, Randomized, Multi-center, Active Controlled, Parallel-group, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution 0.02% and Latanoprost Ophth[NCT02674854]Phase 3750 participants (Actual)Interventional2016-02-29Completed
A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Opht[NCT02558400]Phase 3718 participants (Actual)Interventional2015-09-18Completed
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Primary Rhegmatogenous Detachments and Retinal Detachment Due to Proliferative Vitreoretinopathy or Open-Globe Injury: A Phase I/II Clinical Trial[NCT06033703]Phase 1/Phase 248 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation[NCT03248037]Phase 3120 participants (Actual)Interventional2017-09-05Completed
A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-[NCT03844945]Phase 2215 participants (Actual)Interventional2019-03-19Completed
A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting[NCT03808688]Phase 4261 participants (Actual)Interventional2018-12-27Completed
A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solutio[NCT02057575]Phase 2298 participants (Actual)Interventional2014-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Intraocular Pressure (IOP)

Mean intraocular pressure(IOP) at 08:00, 10:00 and 16:00 hours, at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. (NCT02674854)
Timeframe: 3 months

,,
InterventionmmHg (Mean)
Day 1, 0800 hoursDay 1, 1000 hoursDay 1, 1600 hoursDay 15, 0800 hoursDay 15, 1000 hoursDay 15, 1600 hoursDay 43, 0800 hoursDay 43, 1000 hoursDay 43, 1600 hoursDay 90, 0800 hoursDay 90, 1000 hoursDay 90, 1600 hours
Latanoprost Ophthalmic Solution 0.005%24.7523.2322.5918.1017.6117.0817.9317.3517.0917.9817.4817.14
Netarsudil (AR-13324) Ophthalmic Solution 0.02%24.6623.4022.7619.3517.9917.5319.5218.4017.9519.7218.3017.94
PG324 Ophthalmic Solution24.6923.3322.3716.0615.3115.1616.4315.5415.4516.4515.5815.52

Extent of Exposure

Exposure to study medication in days for all treatment groups (NCT02558400)
Timeframe: 12 months

Interventiondays (Mean)
PG324 Ophthalmic Solution 0.02%/0.005%275.7
AR-13324 Ophthalmic Solution 0.02%266.2
Latanoprost Ophthalmic Solution 0.005%330.4

Intraocular Pressure (IOP)

The primary efficacy variable was mean IOP at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. Secondary analysis were conducted as a part of safety measurements to month 12 on treatment. (NCT02558400)
Timeframe: Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)

,,
InterventionmmHg (Mean)
Day 1, 0800 hoursDay 1, 1000 hoursDay 1, 1600 hoursDay 15, 0800 hoursDay 15, 1000 hoursDay 15, 1600 hoursDay 43, 0800 hoursDay 43, 1000 hoursDay 43, 1600 hoursDay 90, 0800 hoursDay 90, 1000 hoursDay 90, 1600 hours
AR-13324 Ophthalmic Solution 0.02%24.8123.4522.6318.6617.7817.2519.0617.9217.5419.0417.9617.30
Latanoprost Ophthalmic Solution 0.005%24.5923.4323.4317.7417.3617.1117.5817.0616.9717.5316.8816.67
PG324 Ophthalmic Solution24.8423.7222.5915.6814.9314.8316.0415.3915.4316.3715.4115.49

Intraocular Pressure

Intraocular pressure measurement exceeding 24 mm Hg or more than 10 mm Hg greater than the pre-randomization reading. (NCT03248037)
Timeframe: from date of randomization until the date of first documented intraocular pressure elevation exceeding defined threshold up to 9 months

InterventionParticipants (Count of Participants)
Netarsudil11
Placebo18

Intraocular Pressure (IOP)

Mean diurnal IOP within a treatment by Goldman Applanation Tonometry (NCT03844945)
Timeframe: 29 Days

,,,
InterventionmmHg (Mean)
Day 1Day 8Day 15Day 29
Netarsudil Ophthalmic Solution 0.01%20.516.215.916.3
Netarsudil Ophthalmic Solution 0.02%20.315.915.615.4
Netarsudil Ophthalmic Solution 0.04%20.815.715.716.2
Netarsudil Ophthalmic Solution Placebo21.119.819.319.3

Intraocular Pressure (IOP)

"Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry.~Prostaglandin analog (PGA). Fixed dose combination (FDC)." (NCT03808688)
Timeframe: 12 weeks

Interventionpercent change (Mean)
Netarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At Baseline-16.9
Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 Agent-2.3
Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 Agents0.2
Netarsudil Ophth Sol 0.02% Concomitant Therapy-17.0

Intraocular Pressure (IOP)

The primary efficacy endpoint was the mean diurnal IOP across subjects within treatment group at Day 29. (NCT02057575)
Timeframe: Study treatment was administered for 28 days, and outcome measures collected on Day 29

,,,
InterventionmmHg (Mean)
Day 1, Diurnal MeanDay 29, Diurnal Mean
Latanoprost Ophthalmic Solution25.9918.44
Netarsudil (AR-13324) Ophthalmic Solution25.3519.13
PG324 Ophthalmic Solution 0.01%25.1117.33
PG324 Ophthalmic Solution 0.02%25.1216.52

Reviews

11 reviews available for beta-alanine and Intraocular Pressure

ArticleYear
Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature.
    Cornea, 2022, Feb-01, Volume: 41, Issue:2

    Topics: Benzoates; beta-Alanine; Corneal Edema; Epithelium, Corneal; Humans; Intraocular Pressure; Ocular Hy

2022
Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
    Korean journal of ophthalmology : KJO, 2022, Volume: 36, Issue:5

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula

2022
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
    Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:1

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Combinations; Female; Glaucoma; Humans; Intra

2020
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
    Eye (London, England), 2020, Volume: 34, Issue:1

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula

2020
Netarsudil for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Literature Review.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:8

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pressure

2021
Advances in medical therapy for glaucoma.
    Current opinion in ophthalmology, 2021, Mar-01, Volume: 32, Issue:2

    Topics: Administration, Ophthalmic; Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Humans; Intr

2021
Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension.
    European journal of ophthalmology, 2021, Volume: 31, Issue:5

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pr

2021
Netarsudil Ophthalmic Solution 0.02%: First Global Approval.
    Drugs, 2018, Volume: 78, Issue:3

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Clinical Trials as Topic; Drug Approval; Glaucoma,

2018
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
    Ophthalmology, 2018, Volume: 125, Issue:11

    Topics: Antihypertensive Agents; Aqueous Humor; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intra

2018
Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    Drugs of today (Barcelona, Spain : 1998), 2018, Volume: 54, Issue:8

    Topics: Administration, Ophthalmic; Animals; Benzoates; beta-Alanine; Drug Interactions; Eye; Glaucoma, Open

2018
Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.
    Drugs, 2019, Volume: 79, Issue:10

    Topics: Animals; Benzoates; beta-Alanine; Drug Therapy, Combination; Eye; Glaucoma; Humans; Intraocular Pres

2019

Trials

15 trials available for beta-alanine and Intraocular Pressure

ArticleYear
Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
    Veterinary ophthalmology, 2021, Volume: 24 Suppl 1

    Topics: Administration, Ophthalmic; Animals; Benzoates; beta-Alanine; Dog Diseases; Dogs; Female; Glaucoma,

2021
Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.
    Veterinary ophthalmology, 2021, Volume: 24 Suppl 1

    Topics: Animals; Benzoates; beta-Alanine; Dogs; Dose-Response Relationship, Drug; Female; Intraocular Pressu

2021
Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
    Advances in therapy, 2020, Volume: 37, Issue:3

    Topics: Aged; Benzoates; beta-Alanine; Double-Blind Method; Drug Combinations; Endothelium, Corneal; Female;

2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Advances in therapy, 2020, Volume: 37, Issue:4

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao

2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Advances in therapy, 2020, Volume: 37, Issue:4

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao

2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Advances in therapy, 2020, Volume: 37, Issue:4

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao

2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Advances in therapy, 2020, Volume: 37, Issue:4

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao

2020
Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Journal of glaucoma, 2020, Volume: 29, Issue:10

    Topics: Administration, Ophthalmic; Adult; Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Double-Bl

2020
Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
    American journal of ophthalmology, 2021, Volume: 222

    Topics: Adult; Aged; Aged, 80 and over; Benzoates; beta-Alanine; Double-Blind Method; Female; Follow-Up Stud

2021
Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
    American journal of ophthalmology, 2021, Volume: 226

    Topics: Administration, Ophthalmic; Adult; Aged; Aqueous Humor; Benzoates; beta-Alanine; Double-Blind Method

2021
Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
    Advances in therapy, 2021, Volume: 38, Issue:4

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Double-Blind Method; Glaucoma, Open-Angle; Humans;

2021
A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
    Current medical research and opinion, 2021, Volume: 37, Issue:6

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pressure

2021
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
    American journal of ophthalmology, 2018, Volume: 186

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Child;

2018
Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
    American journal of ophthalmology, 2019, Volume: 200

    Topics: Administration, Ophthalmic; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Benzo

2019
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    American journal of ophthalmology, 2019, Volume: 204

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Dose-Response Rela

2019
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
    American journal of ophthalmology, 2019, Volume: 207

    Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Double-Blind Met

2019
Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Ophthalmology, 2015, Volume: 122, Issue:2

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Al

2015
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
    The British journal of ophthalmology, 2016, Volume: 100, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Pachymetry

2016

Other Studies

25 other studies available for beta-alanine and Intraocular Pressure

ArticleYear
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022, Volume: 260, Issue:3

    Topics: Aged; Aged, 80 and over; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula

2022
The Intraocular Pressure Lowering Effect of a Dual Kinase Inhibitor (ITRI-E-(S)4046) in Ocular Hypertensive Animal Models.
    Investigative ophthalmology & visual science, 2021, 10-04, Volume: 62, Issue:13

    Topics: Animals; Benzoates; beta-Alanine; Calcium-Binding Proteins; Disease Models, Animal; Humans; Intraocu

2021
Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma.
    Journal of glaucoma, 2022, 01-01, Volume: 31, Issue:1

    Topics: Benzoates; beta-Alanine; Cataract; Glaucoma; Humans; Intraocular Pressure

2022
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022, Volume: 260, Issue:9

    Topics: Adult; Benzoates; beta-Alanine; Cataract; Humans; Intraocular Pressure; Ocular Hypotension; Pilot Pr

2022
Case Report: Topical Netarsudil in the Treatment of a Neurotrophic Corneal Ulcer.
    Optometry and vision science : official publication of the American Academy of Optometry, 2022, 07-01, Volume: 99, Issue:7

    Topics: Benzoates; beta-Alanine; Corneal Ulcer; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular H

2022
Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil.
    Digital journal of ophthalmology : DJO, 2022, Volume: 28, Issue:8

    Topics: Aged; Benzoates; beta-Alanine; Edema; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pr

2022
Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center.
    Indian journal of ophthalmology, 2022, Volume: 70, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma; Glaucom

2022
Symptomatic Netarsudil-Induced Verticillata.
    JAMA ophthalmology, 2023, Nov-01, Volume: 141, Issue:11

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pressure

2023
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
    Expert opinion on therapeutic patents, 2019, Volume: 29, Issue:10

    Topics: Benzoates; beta-Alanine; Glaucoma; Humans; Intraocular Pressure; Isoquinolines; Ocular Hypertension;

2019
Reversible Corneal Endothelial Abnormalities With Netarsudil.
    Journal of glaucoma, 2020, Volume: 29, Issue:6

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Diseases; Drug Therapy, Combination;

2020
Dose-dependent effects of netarsudil, a Rho-kinase inhibitor, on the distal outflow tract.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2020, Volume: 258, Issue:6

    Topics: Animals; Aqueous Humor; Benzoates; beta-Alanine; Dose-Response Relationship, Drug; Intraocular Press

2020
Reticular Corneal Edema or Corneal Honeycombing in Eyes Treated With Netarsudil: A Case Series.
    Journal of glaucoma, 2020, Volume: 29, Issue:7

    Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Edema; Female; Glaucoma, Open-Angle;

2020
A Patient With Glaucoma With Corneal Edema.
    JAMA ophthalmology, 2020, 08-01, Volume: 138, Issue:8

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Edema; Epithelium, Corneal; Glaucoma, Open

2020
Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil.
    Journal of glaucoma, 2020, Volume: 29, Issue:11

    Topics: Aged; Benzoates; beta-Alanine; Cataract Extraction; Corneal Diseases; Corneal Edema; Descemet Stripp

2020
Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.
    Cornea, 2021, 08-01, Volume: 40, Issue:8

    Topics: Aged; Aged, 80 and over; Benzoates; beta-Alanine; Corneal Edema; Epithelium, Corneal; Humans; Intrao

2021
Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
    European journal of ophthalmology, 2022, Volume: 32, Issue:1

    Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Cohort Studies; Glaucoma; Glaucoma, Open-Angle; Hu

2022
Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
    Cornea, 2021, Jul-01, Volume: 40, Issue:7

    Topics: Administration, Ophthalmic; Aged; Aged, 80 and over; Benzoates; beta-Alanine; Cornea; Corneal Pachym

2021
Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.
    eLife, 2021, 03-30, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antihypertensive Agents; Benzoates; beta-Alanin

2021
Netarsudil-related Eyelid Wound Dehiscence.
    Journal of glaucoma, 2021, Volume: 30, Issue:2

    Topics: Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Eyelids; Glaucoma, Open-Angle;

2021
Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
    Veterinary ophthalmology, 2021, Volume: 24, Issue:6

    Topics: Animals; Antihypertensive Agents; Benzoates; beta-Alanine; Dog Diseases; Dogs; Double-Blind Method;

2021
Current therapeutic options and treatments in development for the management of primary open-angle glaucoma.
    The American journal of managed care, 2017, Volume: 23, Issue:15 Suppl

    Topics: Aqueous Humor; Benzoates; beta-Alanine; Cholinergic Agents; Glaucoma, Open-Angle; Humans; Intraocula

2017
Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015, Volume: 31, Issue:3

    Topics: Animals; Antihypertensive Agents; Benzoates; beta-Alanine; Intraocular Pressure; Male; Models, Anima

2015
Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.
    Bioorganic & medicinal chemistry letters, 2016, 05-15, Volume: 26, Issue:10

    Topics: Animals; Benzoates; beta-Alanine; Disease Models, Animal; Drug Evaluation, Preclinical; Glaucoma, Op

2016
Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes.
    European journal of pharmacology, 2016, Sep-15, Volume: 787

    Topics: Animals; Aqueous Humor; Benzoates; beta-Alanine; Eye; Fluorescent Dyes; Image Processing, Computer-A

2016
Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.
    Experimental eye research, 2017, Volume: 158

    Topics: Administration, Topical; Animals; Axons; Benzoates; beta-Alanine; Blotting, Western; Cell Survival;

2017